Aurobindo confident of FDA OK for banned API plant by year end

By Gareth Macdonald

- Last updated on GMT

Related tags: Pharmaceutical drug

Aurobindo predicts FDA approval
Aurobindo Pharma is still waiting for US FDA re-approval for its Indian cephalosporin plant, but is confident of a decision by the end of the year.

The facility in Chitkul Village, Andhra Pradesh, India – which is known as Unit 6 – was one of two​ for which Aurobindo received warning letters from the US Food and Drug Administration (FDA) in February last year.

Since then unit 6 has been subject of a US export ban that saw sales of the antibiotic active pharmaceutical ingredient (API) slump and prompted customers like Pfizer to rely on other suppliers.

Aurobindo has been working to correct the problems in a process that involved investing in new technologies and calling in a consultant to assess the plant according to company managing director Narayanan Govindarajan.

He told investors at the contract manufacturing organisation’s (CMO) most recent results presentation in August​ that: “We have concluded what improvement we need to make and our consultant has also validated.”

But while these efforts and a subsequent request to the regulator resulted in a second FDA inspection of the cephalosporin facility in late September, Aurobindo is still not allowed to ship products made there to the US.

However, according to Edelweiss Securities analyst Manoj Garg,​ the US inspection team discovered no major problems and Aurobindo is confident it will be re-approved by the FDA in the next three to four months.

Such a decision would be a significant development for the CMO Garg continued, adding that: “Post approval, we expect Aurobindo to launch 3-4 injectables products in the US market, which will aid both growth and profitability going forward​.”

With new launches, higher capacity utilisation and FDA resolution margins are likely to return to 16-18% by FY14E. Moreover, margin in Q1FY13 were also impacted by higher inventory build-up in the US, which will be liquidated over the next 2-3 quarters​.” 

Related news

Show more

Related products

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more

Webinars